Eisai Announces Initiation of Phase III BAN2401 Study in Alzheimer's Disease

Eisai announced that a global Phase III clinical study of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer's disease has been initiated.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.